Janney Montgomery Scott LLC Makes New $793,000 Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Janney Montgomery Scott LLC purchased a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 52,708 shares of the company’s stock, valued at approximately $793,000.

Other institutional investors also recently modified their holdings of the company. Jane Street Group LLC grew its position in shares of Pacira BioSciences by 1,780.2% during the 1st quarter. Jane Street Group LLC now owns 187,531 shares of the company’s stock worth $5,480,000 after buying an additional 177,557 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Pacira BioSciences by 12.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock worth $52,300,000 after buying an additional 198,936 shares during the period. Legato Capital Management LLC grew its position in shares of Pacira BioSciences by 74.0% during the 2nd quarter. Legato Capital Management LLC now owns 52,913 shares of the company’s stock worth $1,514,000 after buying an additional 22,497 shares during the period. WINTON GROUP Ltd acquired a new stake in shares of Pacira BioSciences during the 2nd quarter worth approximately $2,726,000. Finally, GAMMA Investing LLC grew its position in shares of Pacira BioSciences by 229.6% during the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock worth $38,000 after buying an additional 932 shares during the period. Institutional investors and hedge funds own 99.73% of the company’s stock.

Analyst Upgrades and Downgrades

PCRX has been the subject of a number of analyst reports. Royal Bank of Canada boosted their price objective on shares of Pacira BioSciences from $15.00 to $16.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Pacira BioSciences in a report on Friday, November 8th. Raymond James cut shares of Pacira BioSciences from an “outperform” rating to a “market perform” rating in a report on Monday, August 12th. StockNews.com cut shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Monday, August 12th. Finally, HC Wainwright decreased their price objective on shares of Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating for the company in a report on Monday, August 12th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Pacira BioSciences has a consensus rating of “Hold” and an average target price of $23.50.

Pacira BioSciences Stock Performance

Shares of PCRX opened at $16.60 on Monday. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $35.95. The firm has a fifty day simple moving average of $15.81 and a 200 day simple moving average of $20.64. The stock has a market capitalization of $766.47 million, a price-to-earnings ratio of -8.18 and a beta of 0.82. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.